PE20110072A1 - Composicion inmunogenica - Google Patents

Composicion inmunogenica

Info

Publication number
PE20110072A1
PE20110072A1 PE2010000450A PE2010000450A PE20110072A1 PE 20110072 A1 PE20110072 A1 PE 20110072A1 PE 2010000450 A PE2010000450 A PE 2010000450A PE 2010000450 A PE2010000450 A PE 2010000450A PE 20110072 A1 PE20110072 A1 PE 20110072A1
Authority
PE
Peru
Prior art keywords
conjugated
immunogenic composition
proportion
tetanic toxoid
capsular
Prior art date
Application number
PE2010000450A
Other languages
English (en)
Spanish (es)
Inventor
Ralph Leon Biemans
Dominique Boutriau
Carine Capiau
Philippe Denoel
Pierre Duvivier
Jan Poolman
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20110072A1 publication Critical patent/PE20110072A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)
PE2010000450A 2005-06-27 2006-06-23 Composicion inmunogenica PE20110072A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition

Publications (1)

Publication Number Publication Date
PE20110072A1 true PE20110072A1 (es) 2011-02-04

Family

ID=36716943

Family Applications (6)

Application Number Title Priority Date Filing Date
PE2010000450A PE20110072A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2014001334A PE20142165A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2006000720A PE20070499A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2006000719A PE20070163A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
PE2010000444A PE20110096A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica que comprende sacaridos de neisseria meningitidis conjugados a toxoide tetanico
PE2006000718A PE20070123A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica

Family Applications After (5)

Application Number Title Priority Date Filing Date
PE2014001334A PE20142165A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2006000720A PE20070499A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica
PE2006000719A PE20070163A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica de conjugados de sacaridos de n. meningitidis
PE2010000444A PE20110096A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica que comprende sacaridos de neisseria meningitidis conjugados a toxoide tetanico
PE2006000718A PE20070123A1 (es) 2005-06-27 2006-06-23 Composicion inmunogenica

Country Status (36)

Country Link
US (13) US8431136B2 (enExample)
EP (11) EP1896061B1 (enExample)
JP (9) JP5037503B2 (enExample)
KR (7) KR101408113B1 (enExample)
CN (3) CN102218138A (enExample)
AP (1) AP2436A (enExample)
AR (3) AR056397A1 (enExample)
AT (3) ATE516816T1 (enExample)
AU (7) AU2006263936B2 (enExample)
BE (1) BE2012C042I2 (enExample)
BR (5) BRPI0612656B1 (enExample)
CA (5) CA2611964C (enExample)
CY (5) CY1109996T1 (enExample)
DE (1) DE602006013313D1 (enExample)
DK (7) DK1896061T3 (enExample)
EA (4) EA012506B1 (enExample)
ES (9) ES2662651T3 (enExample)
FR (1) FR22C1008I2 (enExample)
HR (4) HRP20100211T1 (enExample)
HU (7) HUE046905T2 (enExample)
IL (8) IL187924A (enExample)
LT (2) LT2351578T (enExample)
LU (2) LU92085I2 (enExample)
MA (4) MA29602B1 (enExample)
MX (5) MX2007016403A (enExample)
MY (3) MY148110A (enExample)
NL (1) NL300549I2 (enExample)
NO (4) NO345422B1 (enExample)
NZ (6) NZ564371A (enExample)
PE (6) PE20110072A1 (enExample)
PL (8) PL1896061T3 (enExample)
PT (8) PT3009146T (enExample)
SI (8) SI2351578T1 (enExample)
TW (5) TWI422386B (enExample)
UA (2) UA95238C2 (enExample)
WO (6) WO2007000341A2 (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180316A1 (en) * 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CN102319427A (zh) 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2611964C (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
US8007807B2 (en) * 2005-09-01 2011-08-30 Novartis Vaccines And Diagnostics Gmbh Multiple vaccination including serogroup C meningococcus
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
MX2008008140A (es) 2005-12-22 2008-09-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia.
US10543265B2 (en) 2006-03-22 2020-01-28 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
SI2066344T1 (sl) 2006-09-07 2011-09-30 Glaxosmithkline Biolog Sa Inaktivirano poliovirusno kombinirano cepivo
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US9610339B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
KR20110050531A (ko) * 2008-08-28 2011-05-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
HRP20160815T1 (hr) 2008-10-27 2016-09-23 Glaxosmithkline Biologicals Sa Postupak pročišćavanja ugljikohidrata iz skupine a streptokoka
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
EP2411045A1 (en) 2009-03-24 2012-02-01 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
SMT202000366T1 (it) 2009-03-24 2020-09-10 Glaxosmithkline Biologicals Sa Proteina legante fattore h di meningococco come adiuvante
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
RU2508126C2 (ru) 2009-04-14 2014-02-27 Новартис Аг Композиции для иммунизации против staphylococcus aureus
AU2010243285B2 (en) * 2009-04-30 2013-06-06 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CN107096020A (zh) 2009-06-22 2017-08-29 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
SA114350400B1 (ar) * 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
NZ598654A (en) 2009-09-02 2014-05-30 Novartis Ag Immunogenic compositions including tlr activity modulators
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
ES2626416T3 (es) * 2009-10-30 2017-07-25 Glaxosmithkline Biologicals Sa Purificación de sacáridos capsulares de Staphilococcus aureus de tipo 5 y de tipo 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
ES2707778T3 (es) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
ES2850973T5 (es) 2010-08-23 2024-09-20 Wyeth Llc Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
WO2013098589A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
RU2634405C2 (ru) * 2012-01-30 2017-10-26 Серум Инститьют Оф Индия Лтд. Иммуногенная композиция
RU2014135522A (ru) 2012-02-02 2016-03-27 Новартис Аг Промоторы для увеличенной экспрессии белка у менингококка
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR112014021658A2 (pt) 2012-03-09 2017-07-11 Pfizer composições de neisseria meningitidis e métodos das mesmas
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
ITMI20121597A1 (it) 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
TR201808684T4 (tr) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Lineer olmayan sakarit konjügatları.
MX366876B (es) 2012-11-30 2019-07-29 Glaxosmithkline Biologicals Sa Antígenos de pseudomonas y combinaciones de antígenos.
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN105007935A (zh) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 用于保护免于白喉和/或破伤风的缀合物
ES2670863T3 (es) 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
AU2014234408B2 (en) * 2013-03-18 2017-04-20 Glaxosmithkline Biologicals S.A. Method of treatment
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
IN2014DE02450A (enExample) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
KR20220080201A (ko) * 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (en) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
EP3131576B1 (en) 2014-04-17 2021-06-30 Medizinische Hochschule Hannover Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
KR20250058066A (ko) * 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
WO2017158480A1 (en) * 2016-03-15 2017-09-21 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel polysaccharide-protein conjugates and process to obtain thereof
SI3506935T1 (sl) * 2016-09-02 2024-06-28 Sanofi Pasteur, Inc. Cepivo proti neisseriji meningitidis
WO2018042015A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
PL3432916T3 (pl) 2016-09-13 2020-04-30 Allergan, Inc. Niebiałkowo stabilzowane kompozycje toksyny clostridium
US11027005B2 (en) * 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
KR20240110660A (ko) 2016-12-30 2024-07-15 박사이트, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
US12383611B2 (en) 2019-09-27 2025-08-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4061412A1 (en) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosage and administration of a bacterial saccharide glycoconjugate vaccine
BR112023009109A2 (pt) 2020-11-13 2024-02-06 Glaxosmithkline Biologicals Sa Carreadores de proteína bacteriana e métodos de conjugação
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
WO2025021712A1 (en) 2023-07-21 2025-01-30 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
HU193083B (en) * 1984-02-22 1987-08-28 Sandoz Ag Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
WO1989011813A1 (fr) 1988-05-31 1989-12-14 KÖNIG-HAUG, Beatrice Systeme de rayonnage
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK0504202T3 (da) 1989-12-14 1995-10-02 Ca Nat Research Council Forbedret meningokok-polysaccharid-konjugat vaccine
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
AU685047B2 (en) 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
JP3626996B2 (ja) 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE69323264D1 (de) 1992-10-27 1999-03-11 American Cyanamid Co Pädiatrische Kombinationsvakzine mit verbesserter Immunogenizität jeder Vakzine komponente
WO1994014086A1 (en) 1992-12-14 1994-06-23 Western Atlas International, Inc. Removable piston bore liner for hydraulically actuated seismic vibrator
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
CA2215933C (en) 1995-03-22 2009-10-13 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
TR199701547T1 (xx) 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
DK1082965T3 (da) 1995-06-23 2009-07-27 Glaxosmithkline Biolog Sa Et vaccinepræparat der omfatter et polysaccharidkonjugatantigen adsorberet på aluminiumphosphat
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
EP0936601B1 (en) 1996-10-23 2002-04-24 Matsushita Electric Industrial Co., Ltd. Optical disc
JP4469026B2 (ja) 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
WO1998026799A1 (en) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU4707097A (en) 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
CA2340692A1 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
WO2000033882A1 (en) † 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
DK1140157T3 (da) 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
AU2875700A (en) 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
DE60043930D1 (de) 1999-03-19 2010-04-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
WO2001000790A1 (en) * 1999-06-25 2001-01-04 American Cyanamid Company Production of the lipidated form of the peptidoglycan-associated lipoproteins of gram-negative bacteria
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
ATE400296T1 (de) 1999-12-02 2008-07-15 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US20030180316A1 (en) 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
AU2001280883A1 (en) * 2000-07-27 2002-02-13 The Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002034771A2 (en) * 2000-10-27 2002-05-02 Chiron Srl Nucleic acids and proteins from streptococcus groups a & b
YU66103A (sh) 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
CA2479118A1 (en) * 2002-03-15 2003-09-25 Wyeth Holdings Corporation Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
ATE419278T1 (de) * 2002-03-26 2009-01-15 Novartis Vaccines & Diagnostic Modifizierte saccharide mit verbesserter stabilität in wasser
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
ATE513560T1 (de) 2002-05-14 2011-07-15 Novartis Vaccines & Diagnostic Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
US20040096461A1 (en) 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
PT1524993E (pt) 2002-08-02 2013-06-12 Glaxosmithkline Biolog Sa Composições de vacina de neisseria compreendendo uma combinação de antigénios
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
SI2353608T1 (sl) * 2002-10-11 2020-12-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
CN1401328A (zh) 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
TW200501981A (en) * 2002-11-01 2005-01-16 Glaxosmithkline Biolog Sa Drying method
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
CN102319427A (zh) * 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
MXPA05009579A (es) * 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Proceso de purificacion para citolisina bacteriana.
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CN104225587B (zh) 2003-05-07 2017-07-21 赛诺菲巴斯德公司 多价脑膜炎球菌衍生的多糖‑蛋白质缀合物及疫苗
PL1631264T5 (pl) 2003-06-02 2018-09-28 Glaxosmithkline Biologicals Sa Kompozycje immunogenne oparte na biodegradowalnych mikrocząstkach zawierających toksoid błonicy i tężca
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
JP2007516181A (ja) 2003-06-23 2007-06-21 アヴェンティス パストゥール インコーポレイテッド 髄膜炎菌血清群ａおよびｃに対する免疫方法
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CN100423774C (zh) * 2003-08-06 2008-10-08 美国政府健康及人类服务部 制备多糖-蛋白轭合物疫苗的方法
US6995363B2 (en) * 2003-08-21 2006-02-07 Applera Corporation Reduction of matrix interference for MALDI mass spectrometry analysis
WO2005032584A2 (en) * 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
SI1961426T1 (sl) * 2003-10-02 2011-10-28 Novartis Ag Kombinirana cepiva proti meningitisu
JP5173194B2 (ja) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
ES2409782T3 (es) * 2004-04-05 2013-06-27 Zoetis P Llc Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
JP5718545B2 (ja) 2004-04-30 2015-05-13 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 髄膜炎菌結合体ワクチン接種
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1793849A2 (en) * 2004-09-22 2007-06-13 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1858920B1 (en) * 2005-02-18 2016-02-03 GlaxoSmithKline Biologicals SA Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0505518D0 (en) † 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN104815327A (zh) * 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
PT1885734E (pt) * 2005-05-06 2015-03-04 Novartis Ag Imunogénios para vacinas contra a meningite-a
CA2611964C (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
US8007807B2 (en) 2005-09-01 2011-08-30 Novartis Vaccines And Diagnostics Gmbh Multiple vaccination including serogroup C meningococcus
EP1922546B1 (en) * 2005-09-05 2010-10-20 GlaxoSmithKline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MX2008008140A (es) * 2005-12-22 2008-09-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacarido capsular de streptococcus pneumonia.
US20080305127A1 (en) 2005-12-23 2008-12-11 Glaxosmithkline Biologicals S.A. Conjugate Vaccines
EP1993604B1 (en) * 2006-03-17 2015-12-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Methods for preparing complex multivalent immunogenic conjugates
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
MX337528B (es) * 2006-03-30 2016-03-09 Glaxosmithkline Biolog Sa Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica.
NZ573931A (en) 2006-06-29 2012-03-30 Craig J Venter Inst Inc Polypeptides from neisseria meningitidis
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
JP2009544614A (ja) 2006-07-21 2009-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒト内在性レトロウイルスポリペプチド組成物およびその使用法
SI2066344T1 (sl) 2006-09-07 2011-09-30 Glaxosmithkline Biolog Sa Inaktivirano poliovirusno kombinirano cepivo
GB0700135D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
JP4858611B2 (ja) * 2007-03-14 2012-01-18 コニカミノルタビジネステクノロジーズ株式会社 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
CN101687028A (zh) * 2007-05-02 2010-03-31 葛兰素史密丝克莱恩生物有限公司 疫苗
NZ581367A (en) 2007-06-04 2012-05-25 Novartis Ag Formulation of meningitis vaccines containing haemophilus influenzae and neisseria meningitidis
US9610339B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR20110050531A (ko) * 2008-08-28 2011-05-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
MX373250B (es) * 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013522177A (ja) * 2010-03-11 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム グラム陰性細菌性、例えば髄膜炎菌性の感染または疾患に対する免疫原性組成物またはワクチン
WO2011155196A1 (ja) * 2010-06-11 2011-12-15 パナソニック株式会社 語音聴取の評価システム、その方法およびそのプログラム
CN104080479B (zh) * 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
GB2495341B (en) * 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
RU2634405C2 (ru) * 2012-01-30 2017-10-26 Серум Инститьют Оф Индия Лтд. Иммуногенная композиция
SG10201608675YA (en) * 2012-05-22 2016-12-29 Novartis Ag Meningococcus serogroup x conjugate
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
EP2928489B1 (en) * 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
BR112017002183A2 (pt) * 2014-08-05 2018-01-16 Glaxosmithkline Biologicals S.A. conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
SI3506935T1 (sl) * 2016-09-02 2024-06-28 Sanofi Pasteur, Inc. Cepivo proti neisseriji meningitidis
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2018215585B2 (en) * 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112020000999A2 (pt) * 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação

Also Published As

Publication number Publication date
KR20080030577A (ko) 2008-04-04
KR101351870B1 (ko) 2014-02-17
US9358279B2 (en) 2016-06-07
AU2006263944B2 (en) 2012-03-01
EP1896064A2 (en) 2008-03-12
TWI407970B (zh) 2013-09-11
HUE047211T2 (hu) 2020-04-28
US20100215686A1 (en) 2010-08-26
HUE045482T2 (hu) 2019-12-30
PE20070163A1 (es) 2007-03-01
AR056397A1 (es) 2007-10-10
SI1896061T1 (sl) 2019-10-30
EP1896062B1 (en) 2010-03-31
PT2878307T (pt) 2019-10-24
JP5297800B2 (ja) 2013-09-25
CY1118646T1 (el) 2017-07-12
IL187924A0 (en) 2008-03-20
US20080199490A1 (en) 2008-08-21
BRPI0612654B1 (pt) 2021-05-04
LUC00247I2 (enExample) 2024-10-04
AU2006263964B2 (en) 2010-05-20
PE20070499A1 (es) 2007-05-21
JP2013018798A (ja) 2013-01-31
ATE462444T1 (de) 2010-04-15
NO345422B1 (no) 2021-01-25
KR20130086087A (ko) 2013-07-30
EA200702577A1 (ru) 2008-06-30
AR056396A1 (es) 2007-10-10
HK1206587A1 (en) 2016-01-15
US20130004532A1 (en) 2013-01-03
TW201414490A (zh) 2014-04-16
NZ564371A (en) 2010-05-28
KR101532068B1 (ko) 2015-06-29
MX2007016405A (es) 2008-03-07
DK1896065T3 (da) 2011-08-29
TWI422386B (zh) 2014-01-11
KR101321056B1 (ko) 2013-10-30
US8398983B2 (en) 2013-03-19
MX2007016402A (es) 2008-03-07
BRPI0612669B8 (pt) 2021-05-25
WO2007000314A3 (en) 2007-05-31
JP5280199B2 (ja) 2013-09-04
BRPI0612655A8 (pt) 2018-01-30
DE602006013313D1 (de) 2010-05-12
HK1116414A1 (en) 2008-12-24
NO20076343L (no) 2008-03-25
BRPI0612655A2 (pt) 2010-11-30
BRPI0612654B8 (pt) 2021-05-25
MY147783A (en) 2013-01-31
KR101359953B1 (ko) 2014-02-21
CN102526723A (zh) 2012-07-04
SI1896063T1 (sl) 2012-03-30
KR20080024222A (ko) 2008-03-17
HUE031380T2 (en) 2017-07-28
AU2006263944A1 (en) 2007-01-04
FR22C1008I1 (fr) 2022-04-29
TWI537001B (zh) 2016-06-11
WO2007000327A1 (en) 2007-01-04
AP2007004274A0 (en) 2007-12-31
NZ564370A (en) 2011-10-28
US9789179B2 (en) 2017-10-17
KR20080025184A (ko) 2008-03-19
SI3009146T1 (sl) 2022-02-28
MA29569B1 (fr) 2008-06-02
EP3009146A1 (en) 2016-04-20
JP2013209395A (ja) 2013-10-10
JP2013107913A (ja) 2013-06-06
AU2010203115C1 (en) 2013-05-02
NO20076363L (no) 2008-03-26
ES2741529T3 (es) 2020-02-11
US20190298822A1 (en) 2019-10-03
US20200000911A1 (en) 2020-01-02
SI1896062T1 (sl) 2010-07-30
WO2007000342A2 (en) 2007-01-04
TW200738259A (en) 2007-10-16
CA2611960C (en) 2015-05-05
AU2006263963A1 (en) 2007-01-04
US20090041802A1 (en) 2009-02-12
CN102526723B (zh) 2017-07-07
CA2612963C (en) 2016-10-18
PL3009146T3 (pl) 2022-02-07
WO2007000341A3 (en) 2007-05-31
PL1896062T3 (pl) 2010-08-31
CY1111827T1 (el) 2015-10-07
AU2006263965A1 (en) 2007-01-04
LU92085I2 (fr) 2012-12-19
SI2878307T1 (sl) 2019-11-29
CA2612957A1 (en) 2007-01-04
CN103083657B (zh) 2016-06-08
EA012506B1 (ru) 2009-10-30
EA200702576A1 (ru) 2008-06-30
IL188046A (en) 2012-03-29
CA2611964C (en) 2016-11-08
CN103083657A (zh) 2013-05-08
NZ564606A (en) 2010-10-29
CA2611964A1 (en) 2007-01-04
EP1896063A1 (en) 2008-03-12
TW201336507A (zh) 2013-09-16
EP1896065B1 (en) 2011-07-20
WO2007000343A2 (en) 2007-01-04
EP1896066A2 (en) 2008-03-12
JP5769688B2 (ja) 2015-08-26
US9931397B2 (en) 2018-04-03
ES2662651T3 (es) 2018-04-09
HUS000497I2 (hu) 2021-03-29
HUE046905T2 (hu) 2020-03-30
PT1896061T (pt) 2019-08-01
CA2611960A1 (en) 2007-01-04
ES2901378T3 (es) 2022-03-22
CA2612980A1 (en) 2007-01-04
EP1896063B1 (en) 2011-12-14
KR20080018226A (ko) 2008-02-27
EP1896061A2 (en) 2008-03-12
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
US9486515B2 (en) 2016-11-08
HUS1200023I1 (hu) 2021-03-29
AU2010203115B2 (en) 2012-03-15
ES2377075T5 (es) 2016-04-29
EP2201961B1 (en) 2018-01-24
PL2351578T3 (pl) 2017-07-31
EP2351578A1 (en) 2011-08-03
HRP20100211T1 (hr) 2010-05-31
EP1896066B8 (en) 2022-01-19
PL1896065T3 (pl) 2011-12-30
CA2612980C (en) 2019-01-15
NO344452B1 (no) 2019-12-09
KR101351873B1 (ko) 2014-02-17
BRPI0612669B1 (pt) 2019-08-13
BRPI0612656B1 (pt) 2021-09-08
ES2621780T3 (es) 2017-07-05
BRPI0612656A2 (pt) 2010-11-30
EP2283857B1 (en) 2019-07-24
WO2007000342A8 (en) 2008-07-10
ES2340711T3 (es) 2010-06-08
US20080193476A1 (en) 2008-08-14
CA2612957C (en) 2016-07-19
CN102218138A (zh) 2011-10-19
DK1896063T3 (da) 2012-03-19
PE20142165A1 (es) 2015-01-09
JP2008543905A (ja) 2008-12-04
US8431136B2 (en) 2013-04-30
NL300549I2 (enExample) 2017-01-03
EA012214B1 (ru) 2009-08-28
HRP20170457T1 (hr) 2017-05-19
BRPI0612669A2 (pt) 2010-11-30
JP2008543908A (ja) 2008-12-04
BRPI0612654A2 (pt) 2012-10-02
KR101408113B1 (ko) 2014-06-16
AU2010212417A1 (en) 2010-09-09
JP2008543907A (ja) 2008-12-04
DK2283857T3 (da) 2019-10-28
IL222346A (en) 2015-07-30
PE20070123A1 (es) 2007-02-08
WO2007000342A3 (en) 2007-05-31
MA29603B1 (fr) 2008-07-01
SI1896065T2 (sl) 2014-12-31
US20130171188A1 (en) 2013-07-04
WO2007000343A3 (en) 2007-05-31
MY148110A (en) 2013-02-28
HRP20120102T1 (hr) 2012-02-29
EP2201961A1 (en) 2010-06-30
ATE516816T1 (de) 2011-08-15
DK1896065T4 (da) 2014-10-20
AU2010203115A1 (en) 2010-08-12
HK1114011A1 (en) 2008-10-24
KR20130122810A (ko) 2013-11-08
EP2878307A1 (en) 2015-06-03
NO345305B1 (no) 2020-12-07
EA013374B1 (ru) 2010-04-30
HRP20110567T1 (en) 2011-09-30
BRPI0612670A2 (pt) 2010-11-30
BE2012C042I2 (enExample) 2021-07-19
EP1896062A1 (en) 2008-03-12
ES2898451T3 (es) 2022-03-07
JP2008543909A (ja) 2008-12-04
ES2750243T3 (es) 2020-03-25
DK2351578T3 (en) 2017-04-24
LTC1896065I2 (lt) 2025-06-10
US10245317B2 (en) 2019-04-02
WO2007000341A2 (en) 2007-01-04
AP2436A (en) 2012-08-31
HUE056842T2 (hu) 2022-03-28
US8846049B2 (en) 2014-09-30
PT2283857T (pt) 2019-10-24
IL188045A0 (en) 2008-03-20
IL213795A (en) 2013-05-30
CA2612963A1 (en) 2007-01-04
PL1896065T5 (pl) 2014-12-31
PT1896063E (pt) 2012-02-13
AU2006263964A1 (en) 2007-01-04
PL2283857T3 (pl) 2020-02-28
MA29993B1 (fr) 2008-12-01
US20150044253A1 (en) 2015-02-12
US10166287B2 (en) 2019-01-01
MY147490A (en) 2012-12-14
FR22C1008I2 (fr) 2024-01-19
MA29602B1 (fr) 2008-07-01
MX2007016236A (es) 2008-03-07
TWI477283B (zh) 2015-03-21
AU2006263936B2 (en) 2010-05-20
DK2878307T3 (da) 2019-10-07
NO342815B1 (no) 2018-08-13
SI1896065T1 (sl) 2011-10-28
US20090252759A1 (en) 2009-10-08
US8883163B2 (en) 2014-11-11
IL214657A0 (en) 2011-09-27
IL213718A0 (en) 2011-07-31
IL213718A (en) 2013-07-31
ATE536884T1 (de) 2011-12-15
EA200702574A1 (ru) 2008-06-30
PT1896062E (pt) 2010-05-17
MX2007016403A (es) 2008-03-07
EP1896065A2 (en) 2008-03-12
BRPI0612670B8 (pt) 2021-05-25
IL188072A0 (en) 2008-03-20
EP2878307B1 (en) 2019-07-24
MX2007016237A (es) 2008-03-07
IL188046A0 (en) 2008-03-20
IL188072A (en) 2017-07-31
LU92085I9 (enExample) 2019-01-04
AR053935A1 (es) 2007-05-23
LT2351578T (lt) 2017-04-10
PL1896063T3 (pl) 2012-04-30
SI2351578T1 (sl) 2017-05-31
BRPI0612670B1 (pt) 2020-04-28
EP3009146B1 (en) 2021-10-20
CY2012027I1 (el) 2015-10-07
JP5037503B2 (ja) 2012-09-26
NZ590204A (en) 2012-02-24
WO2007000314A2 (en) 2007-01-04
EP1896065B2 (en) 2014-09-03
NZ564607A (en) 2011-06-30
NO20076350L (no) 2008-03-26
TW200730187A (en) 2007-08-16
EP2283857A1 (en) 2011-02-16
PL1896061T3 (pl) 2020-02-28
US20170065714A1 (en) 2017-03-09
EP1896066B1 (en) 2021-10-27
US20180064806A1 (en) 2018-03-08
DK1896062T3 (da) 2010-06-28
EP1896061B1 (en) 2019-06-12
LTPA2012019I1 (lt) 2012-11-26
UA95237C2 (uk) 2011-07-25
AU2006263936A1 (en) 2007-01-04
EA200702575A1 (ru) 2008-06-30
SI2283857T1 (sl) 2019-11-29
EA012528B1 (ru) 2009-10-30
JP2008543904A (ja) 2008-12-04
HK1116413A1 (en) 2008-12-24
HRP20110567T4 (xx) 2015-01-16
JP5731737B2 (ja) 2015-06-10
WO2007000322A1 (en) 2007-01-04
JP5965512B2 (ja) 2016-08-03
ES2377075T3 (es) 2012-03-22
EP1896063B2 (en) 2016-03-02
AU2006263963B2 (en) 2010-05-13
PT3009146T (pt) 2021-11-30
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
NZ564605A (en) 2011-01-28
US20090136541A1 (en) 2009-05-28
PT1896065E (pt) 2011-08-31
BRPI0612656A8 (pt) 2018-01-23
CY2012027I2 (el) 2015-10-07
US11241495B2 (en) 2022-02-08
IL187924A (en) 2011-11-30
IL213795A0 (en) 2011-07-31
JP5718960B2 (ja) 2015-05-13
EP2351578B1 (en) 2017-01-18
PE20110096A1 (es) 2011-03-07
DK1896061T3 (da) 2019-08-26
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
HUS2200002I1 (hu) 2022-12-28
CY1109996T1 (el) 2014-09-10
US8329184B2 (en) 2012-12-11
ES2747025T3 (es) 2020-03-09
JP2015134829A (ja) 2015-07-27
UA95238C2 (uk) 2011-07-25
CY1112698T1 (el) 2016-02-10

Similar Documents

Publication Publication Date Title
PE20110072A1 (es) Composicion inmunogenica
MX337528B (es) Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica.
Faulkner Address upon Receiving the Nobel Prize for Literature STOCKHOLM, DECEMBER 10, 1950
PE20191107A1 (es) Composiciones de neisseria meningitidis y metodos respectivos
PE20071058A1 (es) Vacuna de streptococcus pneumoniae
BR0015961A (pt) Antìgeno de neisseria de 85kda
JP2002506648A5 (enExample)
WO2004091543A3 (en) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
TW200502029A (en) Composition and process
BRPI0410341B8 (pt) conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
BRPI0411875A (pt) método de imunização contra os sorogrupos a e c de neisseria meningitidis
WO2009042895A3 (en) Reagents for inducing an immune response
ES2193620T3 (es) Productos de almidon expandido biodegradable y metodo de preparacion.
ECSP066916A (es) Vacuna contra estreptococo agalactiae
WO2008008541A8 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
NZ603854A (en) West nile virus vaccine
BRPI0413906A (pt) composições imunogênicas de hiv, kit e métodos relacionados
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
WO2006103568A3 (en) NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF
Maltseva Dendroflora of Henichesk (Kherson Region, Ukraine)
FR2903574B1 (fr) Granules de cysteine et leurs utilisations a titre d'activateurs de croissance de bifidobacterium animalis lactis.
WO2007075308A3 (en) Vaccine candidates against johne's disease
BRPI0516372A (pt) conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina
TR200902782A1 (tr) Canlı aşı bileşimi

Legal Events

Date Code Title Description
FC Refusal